The A v integrins, which act as cell adhesion molecules, are closely involved with tumor invasion and angiogenesis. In particular, A v B 3 integrin, which is specifically expressed on proliferating endothelial cells and tumor cells, is a logical target for development of a radiotracer method to assess angiogenesis and anti-angiogenic therapy. In this study, a dimeric cyclic RGD peptide E[c(RGDyK)] 2 was labeled with 18 F (t 1/2 = 109.7 min) by using a prosthetic 4-[ 
Introduction
Tumor angiogenesis, the formation of new blood vessels or the growth of blood vessels between a tumor and surrounding tissue, is a complex process regulated through a precise balance of pro-angiogenic and antiangiogenic molecules, which involves complex interactions between extracellular matrix molecules, proteolytic enzymes, and cell adhesion molecules on endothelial cells (ECs) [1, 2] . As most solid tumors are angiogenesis dependent, the ability to develop molecular imaging methods for evaluating angiogenesis is of vital importance to understand the complex process and to monitor target specific anti-angiogenic treatment efficacy. Inhibition of the activity of any of the key regulators in the angiogenic cascade is expected to block tumor angiogenesis. Integrin adhesion receptors regulate cell survival, proliferation, motility, and differentiation through their ability to transduce signals into and out of the cells and to engage in reciprocal interactions with other cellular receptors [3] . The cell surface adhesion and signaling receptor a v b 3 integrin, which is highly expressed in tumor cells of various origin and activated ECs in growing tumors but not on normal cells and quiescent ECs, has been identified as a marker for angiogenic vascular tissue and potentially can be used as a target for diagnostic and therapeutic agents aimed at tumor angiogenesis [4] .
Two a v -integrin antagonists-vitaxin, a humanized antibody [5] , and cilengitide [6] , a cyclic peptide mimicking the RGD ligand recognition peptidic domain common to a v -integrin ligands-are in phase II clinical trials [4] . Due to their better pharmacokinetics and oral bioavailability, small synthetic heterocyclic inhibitors are also being developed as successors to peptide-derived agents [7] . Other strategies include radiolabeled cyclic RGD peptides for internal radiotherapy [8] , and combination of integrin antagonists and radioimmunotherapy for enhanced therapeutic synergy [9] . The ability to rapidly and accurately detect tumor growth and metastasis is of great importance for implementation of tailored therapeutic regimens [10] . We and others have recently labeled cyclic RGD peptides with 18 F [11 -17] and 64 Cu [14] for positron emission tomography (PET)
imaging of a v b 3 -integrin expression in murine tumor models. The conjugation labeling of small cyclic RGD peptides with the prosthetic labeling group 4-[ 18 F]fluorobenzoyl significantly increased lipophilicity of the peptide and led to unfavorable hepatobiliary excretion and rapid tumor washout of the resulting PET tracer [11, 12, 14] . The clinical potential of this type of radiotracer is thus limited due to unfavorable biodistribution, including very high activity accumulation in the lower abdomen [11, 12, 14] . Haubner et al. [15, 16] Additionally, decreased biliary excretion minimized intestinal retention of the activity and increased tumor-tonontumor ratios [13] . Specific recognition of a peptide by a given receptor depends on the specific configuration of the peptide side-chain with regard to its ability to fit in the receptor binding sites. A multimeric peptide with two or more monomeric units connected via semi-rigid molecular linkers may achieve improved binding avidity and specificity through multiple, weakly cooperative interactions [18] . It was recently reported that dimeric and multimeric cyclic RGD peptides have higher receptor binding affinity in vitro [19] and better tumor retention in vivo [19, 20] . This is presumably due to polyvalency, which gives rise to an enhanced binding and steric stabilization [21] . The aim of the study presented here was to compare the tumor targeting and in vivo kinetics of the 18 
Materials and Methods

Materials
All reagents, unless otherwise specified, were of analytical grade and commercially obtained. Cyclic RGD peptide c(RGDyK) was synthesized via solution cyclization of the fully protected linear pentapeptide H-GlyAsp(OtBu)-D-Tyr(OtBu)-Lys(Boc)-Arg(Pbf)-OH, followed by TFA deprotection [22] . FB-c(RGDyK) was prepared earlier by our group [14] . Dimeric RGD peptide E[c(RGDyK)] 2 was prepared by coupling Boc-Glu-OH with two equivalents of monomeric RGD peptide c(RGDyK) followed by TFA cleavage [23] . Sep-Pak cartridge, washed with water and eluted with 200 mL portions of 80% ethanol. The ethanol fractions were pooled and evaporated to a small volume. The activity was reconstituted in phosphate-buffered saline and passed through a 0.22-mm Millipore filter into a sterile multidose vial for use in animal experiments.
Receptor Binding Assay
Primary human brain capillary endothelial cells (HBCECs) were isolated, characterized, and grown in RPMI-1640 medium with 10% FBS in 5% CO 2 at 37°C as previously described [24] ; the cells were used between passages 5 and 14.
125 I-c(RGDyK) (specific activity 1700 Ci/mmol) was prepared via the chloramine-T method according to a reported procedure [21] . For competitive integrin receptor binding assay studies, Costar 24-well plates were seeded with 2 Â 10 5 BCEC cells/well for 2 hr and then rinsed twice with binding buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 2 mM CaCl 2 , 1 mM MgCl 2 , 1 mM MnCl 2 , and 0.1% bovine serum albumin) [24] . The plate was incubated with 125 I-c(RGDyK) in the presence of increasing concentrations of different RGD peptide analogues (0 -1000 nM). The total incubation volume was adjusted to 400 mL. After the cells were incubated for 2 hr at 4°C, the supernatant was removed, and the cells were washed twice with cold binding buffer and then solubilized with 0.5% SDS. Radioactivity was determined using a NaI(Tl) gamma counter (Packard, Meriden, CT). The IC 50 values were calculated by fitting the data by nonlinear regression using GraphPad Prism (GraphPad Software, San Diego, CA). Experiments were carried out with triplicate samples.
Tumor Models
Animal experiments were conducted under a protocol approved by the USC Institutional Animal Care and Use Committee (IACUC). Female athymic nude mice (nu/nu) obtained from Harlan (Indianapolis, IN) at 4 -5 weeks of age were injected subcutaneously in the right front leg with 2 Â 10 6 U87MG glioblastoma cells suspended in 150 mL Eagle's minimum essential medium (EMEM). When the tumors reached 0.4-0.6 cm in diameter (14 -18 days after implant), the mice were used for biodistribution and micro-PET imaging experiments. with ketamine/xylazine at 1 hr pi and then centered in the FOV of the micro-PET. Mice were scanned for 15 min, and the raw data were framed into one static frame without attenuation correction. The micro-PET was calibrated in terms of absolute activity concentration (nCi/ cc) by imaging a plastic bottle approximating the dimensions of a mouse body and filled with a known concentration of 18 F.
Whole-Body Autoradiography
Autoradiography was performed using a Packard Cyclone Storage Phosphor Screen system (Downers Grove, IL) and a Bright 5030/WD/MR cryomicrotome (Hacker Instruments, Fairfield, NJ). In order to correlate the results obtained from micro-PET and whole-body autoradiography, tumor-bearing mice were sacrificed under ketamine/xylazine anesthesia at 1 hr pi, followed by micro-PET imaging and subsequently cryosectioning for autoradiography. This procedure was followed in order to eliminate the possibility of change in tracer biodistribution between micro-PET and autoradiography. Immediately after micro-PET scanning, the euthanized mouse was frozen in dry ice and isopropyl alcohol bath for 2 min. The body was then embedded in 4% carboxymethyl cellulose (CMC) (Aldrich, Milwaukee, WI) in water mixture within a stainless steel mold. The mold was placed in the dry ice and isopropyl alcohol bath for 5 min and then into a À20°C freezer for 1 hr. The walls of the mold were then removed, and the frozen block was mounted in the cryomicrotome. The block was cut into 50 mM sections, and desired sections were digitally photographed and then captured for autoradiography. The sections were transferred into a chilled film cassette containing a Super Resolution screen (spatial resolution 0.1 mm; Packard) and kept there overnight at À20°C. Screens were laser-scanned with the Packard Cyclone.
Statistical Analysis
The data are expressed as mean ± SD. Means were compared using one-way analysis of variance (ANOVA) and Student's t test. A p value of < .05 was considered significant.
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All RGD peptide analogues tested in the displacement assays showed the expected sigmoid curves (Figure 2 examined. Consequently, the tumor-to-kidney ratio for the monomeric RGD peptide was higher than for the dimeric RGD peptide (2.8 ± 0.4 for [ Figure 6A . The tumor was clearly visible, with high contrast to contralateral background (ratio: 9.5 ± 0.8).
Prominent uptake was also observed in the gallbladder and urinary bladder. Liver uptake was significantly lower than tumor uptake ( p < .001), and activity accumulation in the kidneys was slightly higher than in tumor, which agreed well with the data obtained from direct tissue sampling. Notice that, at the time of imaging, the activity in the intestinal tracts was very low, resulting in a very high-quality image and favorable tumor-to-nontumor ratios. As expected, no activity accumulation was observed in the normal brain, presumably due to a low level of a v -integrin expression in the intact blood -brain barrier [21, 25] . Figure 6B . U87MG tumor on the right hind leg was visible with contrast to contralateral background, however, excessive activity accumulation in the intestinal tracts eliminated its possibility to visualize tumors in the lower abdomen [12, 14] . Quantification of tumor and major organ activity accumulation in micro-PET scans was performed on coronal views using regions of interest (ROIs) that encompassed entire organs. Uptake in the U87MG tumor, liver, and kidneys was calculated as 4.4 ± 0.6, 0.9 ± 0.1, and 3.6 ± 1.2 %ID/g, respectively. These results were in good agreement with the biodistribution data obtained at 1 hr pi except for the tumor, which was underestimated due to partial volume effect. For one mouse, micro-PET images obtained following injection of Dysangiogenesis is involved in most of the major human pathologies [25] . Angiogenic properties of tumors are considered to be critical determinants of the potential for growth and metastasis. Angiogenic therapies have received a great deal of attention in recent years; methods to identify the angiogenic phenotypes of tumors and evaluate the efficacy of these therapies would be of great significance. Integrin receptors are implicated in many pathological processes, such as osteoporosis, misregulated angiogenesis (e.g., rheumatoid arthritis or retinopathy), thrombosis, and inflammation, as well as tumor growth and tumor metastasis [26] . Overexpression of a v b 3 integrin on the cell surfaces of tumor cells and activated ECs compared with resting ECs suggests the application of suitably labeled a v b 3 antagonists for imaging of receptor density levels in a v b 3 -positive tumors. Potential antagonists include antibodies, cyclic RGD peptides, peptidomimetics of the confined RGD sequence, or small molecules. However, genetic ablation of a v integrins in mice has been associated with enhanced pathological angiogenesis [27] . This seemingly paradoxical finding implies that the exact role of a v in tumor angiogenesis is yet to be established. It is possible that a v integrins are negative regulators of angiogenesis and that the drugs targeting them may be acting as agonists rather than antagonists [28] .
Glioblastoma multiforme, the most malignant astroglial-derived tumor, grows as an adherent mass and locally invades normal brain [29] . Both brain capillary and brain tumor cells express high levels of a v b 3 and a v b 5 integrins in vitro and in vivo [30] , as also observed in human brain tumor specimens [31] . EMD 121974, c(RGDf[NMe]V), an a v -integrin antagonist, detaches both the a v -integrin-expressing brain capillary and brain tumor cells from the matrix proteins vitronectin and tenascin, resulting in significant apoptosis of both cell types [32] . Also, daily administration of EMD 121974 inhibited growth of a glioblastoma (U87MG) cell line xenotransplanted into the forebrain of nude mice resulting in increased survival [32] . Suitably labeled RGD peptide may be used to visualize brain tumor growth, quantify integrin receptor expression, and follow antiintegrin treatment efficacy, as well as to develop more potent anti-integrin drugs based on the tracer targeting ability and in vivo kinetics. Because of the very precise design of their configuration, modification and labeling of peptidomimetics and small molecule antagonists of a v b 3 integrin usually eliminate the receptor binding characteristics of such ligands. Furthermore, the lipophilicity of these types of ligands further limits their applicability for diagnostic imaging of a v b 3 -integrin expression. On the other hand, cyclic RGD peptides, with suitable metabolic stability and nanomolar binding affinity for a v b 3 integrin, are ideal for development of suitably labeled probes for tumor visualization, a v b 3 -integrin quantification in vivo, and assessment of anti-integrin treatment efficacy. Cyclic RGD peptides have been labeled with 18 F [11 -17] and 64 Cu [14] for PET, and 111 In and 99m Tc [8, 19, 33, 34] for SPECT imaging studies. In addition, antibodies have been attached to the surface of microbubbles and liposomes for contrast-enhanced ultrasound [35] and magnetic resonance imaging [36] of tumor angiogenesis, respectively. Although g-emitting radiolabels are more readily available and in general have longer half-lives relative to b + -emitting radionuclides, PET cameras have much higher sensitivity, better spatial resolution, and more accurate attenuation correction, and therefore better quantitative accuracy, than SPECT scanners [37] . The acquisition of higher count statistics is particularly valuable for detecting the fewest possible cells per unit volume with the least amount of radioactivity. We expect PET imaging with the 18 F-labeled dimeric RGD peptide described here to provide higher sensitivity and resolution for early tumor detection and assessment of tumor treatment efficacy than SPECT imaging with 111 In-and 99m Tc-labeled peptide analogs. 18 F-labeled monomeric RGD peptides, labeled either via electrophilic [17] or nucleophilic [11 -14] substitution, have encountered the problems of rapid tumor washout and unfavorably high hepatobiliary excretion. Insertion of a sugar amino acid between the F-18 label and the RGD ligand increased the hydrophilicity of the peptide, which brought about improved in vivo pharma- 18 F through the 4-fluorobenzoyl moiety showed both renal and hepatobiliary excretion pathways, resulting in significant activity accumulation in the gallbladder, kidneys, and urinary bladder ( Figure 6B ). The affinity and specificity of the radiotracer for a v integrins and relatively slow blood clearance of the radiotracer might be responsible for the prominent tumor retention. It has been proposed by several groups that the receptor binding characteristics of dimeric and multimeric RGD peptides would be better than that of monomeric RGD peptide based upon polyvalency [18] . Simultaneous binding of multiple RGD motifs within a single molecule to one integrin or binding of multiple integrins to a single multimeric RGD peptide induces cooperativity, entropically enhanced affinity, and steric stabilization [18] . Immobilized human placental a v b 3 -receptor ELISA assays have indicated a more avid binding of the dimer than the monomeric RGD analogue [19] . Tc [19] . It has been demonstrated that uptake of the dimer is higher than that of the monomer in most organs and tissues, but kidney uptake is also higher for the dimer [19] . Because kidneys received the highest radiation dose among normal tissues and seems to be the doselimiting organ for the dimeric RGD peptide tracer, further modification of the radioligand is thus needed to obviate too high a renal dose.
Maintenance of integrin receptor binding affinity was previously tested in HBCECs, which are known to express high levels of a v b 3 and a v b 5 integrins [30] . Dimeric RGD peptide revealed higher integrin receptor affinity than the monomeric analog. Fluorobenzoyl group labeling decreased the receptor binding affinity in vitro for both monomeric and dimeric RGD peptides, which might be attributed to the added hindrance upon substitution of the primary amines. In the current study, higher uptake of [ 18 (Figure 4 ) might be attributed to more effective reabsorption of the dimeric RGD peptide and its major metabolite into the negatively charged proximal renal tubular cells than that of the monomeric RGD analogue [8, 19] . Whether the increased tumor targeting of dimeric RGD peptide was due to cooperative binding or pharmacological effects remains to be determined since there is no direct evidence about whether the spatial arrangement and separation of two RGD moieties is optimal for multiple cell surface integrin binding. Receptor-specific tumor uptake of [ 18 F]FB-E[c (RGDyK)] 2 was demonstrated by effective blocking of activity accumulation in U87MG glioblastoma xenograft resulting from coinjection of the radiotracer with monomeric RGD peptide c(RGDyK), which reportedly has high affinity and specificity for a v b 3 integrin [22] . It is unclear at this stage whether the visualization of the tumor is du to enhanced integrin expression on the neovasculature or enhanced integrin expression on tumor cells. Further validation of the noninvasive PET imaging requires correlation of the magnitude of tumor uptake with receptor density, which can be determined independently using antibodies that are specific to human a v b 3 integrin (U87MG tumor cells) and to mouse a v and/or b 3 integrin (ECs). In order to address the ultimate goal of imaging in patients, model systems with intermediate integrin expression and negative controls should also be studied in order to represent the full extent of human presentations. Since PEGylation of monomeric RGD peptide significantly improved in vivo kinetics of the RGD peptide without compromising tumor-targeting efficacy [13, 22] , we expect that PEGylation may further enhance integrin targeting and improve the biodistribution of the dimeric RGD peptide tracer.
